At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,156 enrolled
Drug / intervention
Selexipag +1 moredrug
Likely dose
Selexipag 200 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
In Brief
A Phase 3 clinical trial evaluating Selexipag and Placebo for Pulmonary Arterial Hypertension. Completed, enrolled 1,156 participants across 182 sites in 39 countries.
Detailed Summary
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesArgentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Peru, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedApr 2010
Primary CompletionApr 2014
Study CompletionOct 2014
TodayJul 2026
First PostedApr 19, 2010
Enrollment StartDec 1, 2009
Primary CompletionApr 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.2 years ago
Interventions
Selexipagdrug
Selexipag 200 µg tablets
Placebodrug
Placebo tablets matching selexipag